Catalyst Pharmaceuticals Inc (CPRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Catalyst Pharmaceuticals Inc stock (CPRX) is currently trading at $23.07. Catalyst Pharmaceuticals Inc PE ratio is 13.57. Catalyst Pharmaceuticals Inc PS ratio (Price-to-Sales) is 4.76. Analyst consensus price target for CPRX is $34.00. WallStSmart rates CPRX as Hold.
- CPRX PE ratio analysis and historical PE chart
- CPRX PS ratio (Price-to-Sales) history and trend
- CPRX intrinsic value — DCF, Graham Number, EPV models
- CPRX stock price prediction 2025 2026 2027 2028 2029 2030
- CPRX fair value vs current price
- CPRX insider transactions and insider buying
- Is CPRX undervalued or overvalued?
- Catalyst Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- CPRX Piotroski F-Score and Altman Z-Score
- CPRX analyst price target and Smart Rating
Catalyst Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
CPRX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Catalyst Pharmaceuticals Inc (CPRX)
CPRX trades 110% above its Graham fair value of $11.42, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Catalyst Pharmaceuticals Inc (CPRX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, profit margin. Concerns around eps growth. Fundamentals are solid but monitor weak areas for improvement.
Catalyst Pharmaceuticals Inc (CPRX) Key Strengths (5)
Every $100 of shareholder equity generates $26 in profit
Keeps $41 of every $100 in revenue after operating costs
Keeps $36 of every $100 in revenue as net profit
89.11% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Catalyst Pharmaceuticals Inc (CPRX) Areas to Watch (4)
Earnings declining -6.40%, profits shrinking
Premium valuation at 4.8x annual revenue
Modest revenue growth at 7.60%
Fairly priced relative to book value
Catalyst Pharmaceuticals Inc (CPRX) Detailed Analysis Report
Overall Assessment
This company scores 59/100 in our Smart Analysis, earning a C grade. Out of 9 metrics analyzed, 5 register as strengths (avg 9.4/10) while 4 fall into concern territory (avg 3.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Profit Margin. Profitability is solid with Return on Equity at 25.50%, Operating Margin at 40.50%, Profit Margin at 36.40%.
The Bear Case
The primary concerns are EPS Growth, Price/Sales, Revenue Growth. Some valuation metrics including Price/Sales (4.76), Price/Book (2.92) suggest expensive pricing. Growth concerns include Revenue Growth at 7.60%, EPS Growth at -6.40%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 25.50% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 7.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Operating Margin) and negatives (EPS Growth, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CPRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CPRX's Price-to-Sales ratio of 4.76x trades at a deep discount to its historical average of 339.05x (7th percentile). The current valuation is 100% below its historical high of 1514.28x set in Aug 2019, and 38% above its historical low of 3.45x in Dec 2020. Over the past 12 months, the PS ratio has compressed from ~6.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Catalyst Pharmaceuticals Inc (CPRX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Catalyst Pharmaceuticals Inc is a mature, profitable business with steady cash generation. Revenue reached 589M with 8% growth year-over-year. Profit margins are strong at 36.4%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 2550.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 36.4% and operating margin of 40.5% demonstrate strong pricing power and operational efficiency.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Catalyst Pharmaceuticals Inc.
Bottom Line
Catalyst Pharmaceuticals Inc is a well-established business delivering consistent profitability with 36.4% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Catalyst Pharmaceuticals Inc(CPRX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.